{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:21Z","timestamp":1792723101668,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neurot.2026.e01080","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:12:28Z","timestamp":1789575148000},"page":"e01080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Accelerating discovery: Transformative clinical trial models in neuro-oncology"],"prefix":"10.1016","volume":"23","author":[{"given":"Amy J.","family":"Wisdom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifaquat","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2026.e01080_bib1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/1078-0432.CCR-21-2750","article-title":"Glioblastoma clinical trials: current landscape and opportunities for improvement","volume":"28","author":"Bagley","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neurot.2026.e01080_bib2","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/neuonc\/noy027","article-title":"The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?","volume":"20","author":"Vanderbeek","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01080_bib4","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.neurot.2026.e01080_bib6","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.ejca.2004.01.008","article-title":"Five-year change in statistical designs of phase II trials published in leading cancer journals","volume":"40","author":"Thezenas","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.neurot.2026.e01080_bib7","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1158\/1078-0432.CCR-10-0669","article-title":"Analysis of the yield of phase II combination therapy trials in medical oncology","volume":"16","author":"Maitland","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neurot.2026.e01080_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/neuonc\/nox144","article-title":"Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma","volume":"20","author":"Mandel","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/neuonc\/noq203","article-title":"Clinical trial end points for high-grade glioma: the evolving landscape","volume":"13","author":"Reardon","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib10","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1200\/JCO.2009.25.5489","article-title":"Comparison of error rates in single-arm versus randomized phase II cancer clinical trials","volume":"28","author":"Tang","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib11","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1007\/s13311-022-01284-x","article-title":"Novel clinical trial designs in neuro-oncology","volume":"19","author":"Saraf","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2026.e01080_bib12","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(23)00005-0","article-title":"Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference","volume":"24","author":"Rahman","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib13","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/neuonc\/noz097","article-title":"To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs","volume":"21","author":"Vanderbeek","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib14","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib15","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S1470-2045(25)00492-9","article-title":"Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1\/2 trial","volume":"26","author":"Woodworth","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11060-020-03408-9","article-title":"Convection-enhanced drug delivery for glioblastoma: a review","volume":"151","author":"D'Amico","year":"2021","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib18","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1038\/s41467-020-19225-7","article-title":"Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy","volume":"11","author":"Gregory","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2026.e01080_bib19","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/neuonc\/noae276","article-title":"A hitchhiker's guide to cerebrospinal fluid biomarkers for neuro-oncology","volume":"27","author":"Riviere-Cazaux","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib20","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib21","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: a report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified criteria for radiographic response assessment in glioblastoma clinical trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2026.e01080_bib23","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"Rano 2.0: Update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib24","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/neuonc\/noad002","article-title":"Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival","volume":"25","author":"Ellingson","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib25","article-title":"Rtog 0825: phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM)","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.neurot.2026.e01080_bib26","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e01080_bib27","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib28","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/ana.410230408","article-title":"Successful chemotherapy for recurrent malignant oligodendroglioma","volume":"23","author":"Cairncross","year":"1988","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2026.e01080_bib29","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1093\/neuonc\/noaf118","article-title":"Response Assessment in Neuro-Oncology (RANO) 2009-2025: broad scope and implementation-A progress report","volume":"27","author":"van den Bent","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib30","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-24-3439","article-title":"FDA approval summary: tovorafenib for relapsed or refractory BRAF-Altered pediatric low-grade glioma","volume":"31","author":"Singh","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neurot.2026.e01080_bib31","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1093\/neuonc\/noaf173","article-title":"The use of minor response, volumetric assessment, and growth rate kinetics as endpoints in grade 1-3 glioma clinical trials: a RANO perspective","volume":"27","author":"van den Bent","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib32","article-title":"Evaluation of early metabolic changes following vorasidenib using FET PET in patients with IDH-mutant gliomas","volume":"6","author":"Galldiks","year":"2024","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.neurot.2026.e01080_bib33","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1093\/neuonc\/noae078","article-title":"PET imaging of gliomas: status quo and quo vadis?","volume":"26","author":"Galldiks","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/nop\/npae099","article-title":"Perfusion MRI-based differentiation between early tumor progression and pseudoprogression in glioblastoma and its use in clinical practice","volume":"12","author":"van Dorth","year":"2025","journal-title":"Neuro-Oncol Pract"},{"key":"10.1016\/j.neurot.2026.e01080_bib35","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.3390\/cancers14133197","article-title":"Magnetic resonance spectroscopy in diagnosis and follow-up of gliomas: State-of-the-art","volume":"14","author":"Galijasevic","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neurot.2026.e01080_bib36","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","article-title":"PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/nop\/npw034","article-title":"Clinical trial endpoints for patients with gliomas","volume":"4","author":"Taylor","year":"2017","journal-title":"Neuro-Oncol Pract"},{"key":"10.1016\/j.neurot.2026.e01080_bib38","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/neuonc\/not088","article-title":"Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2","volume":"15","author":"Alexander","year":"2013","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e01080_bib40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jnci\/djz167","article-title":"Master protocol trial design for efficient and rational evaluation of novel therapeutic oncology devices","volume":"112","author":"Bitterman","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.neurot.2026.e01080_bib41","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/biom.12668","article-title":"Bayesian response-adaptive designs for basket trials","volume":"73","author":"Ventz","year":"2017","journal-title":"Biometrics"},{"key":"10.1016\/j.neurot.2026.e01080_bib42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.seminoncol.2014.05.002","article-title":"Molecular analysis for therapy choice: NCI MATCH","volume":"41","author":"Conley","year":"2014","journal-title":"Semin Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.currproblcancer.2017.05.003","article-title":"Considerations of developing an NGS assay for clinical applications in precision oncology: the NCI-MATCH NGS assay experience","volume":"41","author":"Lih","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.neurot.2026.e01080_bib44","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations","volume":"389","author":"Bouffet","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e01080_bib45","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e01080_bib46","series-title":"U.S. food and drug administration","article-title":"FDA approves pembrolizumab for adults and children with TMB-H solid tumors","year":"2024"},{"key":"10.1016\/j.neurot.2026.e01080_bib47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib48","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/neuonc\/noy161","article-title":"N2M2 (NOA-20) phase I\/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma","volume":"21","author":"Wick","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib49","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1038\/s41591-025-03928-9","article-title":"Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1\/2a N2M2 umbrella trial","volume":"31","author":"Wick","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2026.e01080_bib50","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jama.2021.22507","article-title":"How to use and interpret the results of a platform trial: users' Guide to the Medical Literature: users' guide to the medical literature","volume":"327","author":"Park","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.neurot.2026.e01080_bib51","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1158\/1078-0432.CCR-17-0764","article-title":"Adaptive global innovative learning environment for glioblastoma: GBM AGILE","volume":"24","author":"Alexander","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neurot.2026.e01080_bib52","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1200\/JCO.23.00493","article-title":"Inaugural results of the individualized screening trial of innovative glioblastoma therapy: a phase II platform trial for newly diagnosed glioblastoma using Bayesian adaptive randomization","volume":"41","author":"Rahman","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib53","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0140-6736(24)01295-9","article-title":"Bayesian statistics for clinical research","volume":"404","author":"Goligher","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2026.e01080_bib54","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S1470-2045(21)00488-5","article-title":"Leveraging external data in the design and analysis of clinical trials in neuro-oncology","volume":"22","author":"Rahman","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib55","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.annonc.2021.12.015","article-title":"External control arms in oncology: current use and future directions","volume":"33","author":"Mishra-Kalyani","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib56","series-title":"Considerations for the design and conduct of externally controlled trials for drug and biological products","year":"2023"},{"key":"10.1016\/j.neurot.2026.e01080_bib57","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/neuonc\/noaa149","article-title":"Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review","volume":"22","author":"Vogelbaum","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib58","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nature11287","article-title":"A restricted cell population propagates glioblastoma growth after chemotherapy","volume":"488","author":"Chen","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2026.e01080_bib59","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaf190","article-title":"Spatial profiling of longitudinal glioblastoma reveals consistent changes in cellular architecture, post-treatment","author":"Ajaib","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib60","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41588-025-02168-4","article-title":"Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics","volume":"57","author":"Spitzer","year":"2025","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurot.2026.e01080_bib61","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/ng.3590","article-title":"Clonal evolution of glioblastoma under therapy","volume":"48","author":"Wang","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurot.2026.e01080_bib62","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1101\/gr.180612.114","article-title":"Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution","volume":"25","author":"Kim","year":"2015","journal-title":"Genome Res"},{"key":"10.1016\/j.neurot.2026.e01080_bib63","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/s41588-025-02167-5","article-title":"The multilayered transcriptional architecture of glioblastoma ecosystems","volume":"57","author":"Nomura","year":"2025","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurot.2026.e01080_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adv2881","article-title":"Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses","volume":"17","author":"Ling","year":"2025","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2026.e01080_bib65","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1200\/JCO.23.01621","article-title":"Systematic review of cerebrospinal fluid biomarker discovery in neuro-oncology: a roadmap to standardization and clinical application","volume":"42","author":"Mikolajewicz","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1129627","article-title":"Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures","volume":"13","author":"Alcaniz","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib67","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2024.11.010","article-title":"Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy","volume":"32","author":"Logun","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.neurot.2026.e01080_bib68","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202318144","article-title":"Single-cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma","volume":"15","author":"Finotto","year":"2023","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.neurot.2026.e01080_bib69","article-title":"Personalized targeted glioblastoma therapies by ex vivo drug screening: study protocol of the Advanced brain Tumor TheRApy Clinical Trial (ATTRACT)","volume":"7","author":"Berghoff","year":"2025","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.neurot.2026.e01080_bib70","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/s41591-024-03224-y","article-title":"High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity","volume":"30","author":"Lee","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2026.e01080_bib71","article-title":"Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial","volume":"4","author":"Ranjan","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.neurot.2026.e01080_bib72","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41698-024-00753-0","article-title":"CAR-T cell therapy for the treatment of adult high-grade gliomas","volume":"8","author":"Park","year":"2024","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib73","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2026.e01080_bib74","first-page":"601","article-title":"Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients","volume":"22","author":"Lee","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib76","year":"2024"},{"key":"10.1016\/j.neurot.2026.e01080_bib77","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/neuonc\/noad242","article-title":"Defining interventions and metrics to improve diversity in CNS clinical trial participation: a SNO and RANO effort","volume":"26","author":"Budhu","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01080_bib78","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/jamia\/ocab228","article-title":"A systematic review on natural language processing systems for eligibility prescreening in clinical research","volume":"29","author":"Idnay","year":"2021","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.neurot.2026.e01080_bib79","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cmet.2025.10.022","article-title":"Digital twins for in vivo metabolic flux estimations in patients with brain cancer","volume":"38","author":"Meghdadi","year":"2026","journal-title":"Cell Metab"},{"key":"10.1016\/j.neurot.2026.e01080_bib80","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3390\/cancers18030491","article-title":"MRI-based radiomics for non-invasive prediction of molecular biomarkers in gliomas","volume":"18","author":"Agosti","year":"2026","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neurot.2026.e01080_bib81","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.neurot.2026.e01080_bib82","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2026.e01080_bib83","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/acf023","article-title":"Geometric evaluations of CT and MRI based deep learning segmentation for brain OARs in radiotherapy","volume":"68","author":"Alzahrani","year":"2023","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.neurot.2026.e01080_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109663","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radiother Oncol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:55:15Z","timestamp":1792720515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926002503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":82,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1878747926002503"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01080","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accelerating discovery: Transformative clinical trial models in neuro-oncology","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e01080"}}